A phase I/II study comparing regimen schedules of gemcitabine and docetaxel in Japanese patients with stage IIIB/IV non-small cell lung cancer.

Conclusions: Gemcitabine 1000 mg/m 2 on days 1 and 8 plus docetaxel 50 mg/m 2 on day 8 has comparable efficacy and more tolerable toxicities than previously reported platinum-based regimens. These results should be verified by a phase III study.